Last update 16 May 2025

Ecallantide

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
Ecallantide (genetical recombination) (JAN), Ecallantide (USAN/INN), CB-500929
+ [5]
Target
Action
inhibitors
Mechanism
KLKB1 inhibitors(Plasma kallikrein inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (01 Dec 2009),
RegulationOrphan Drug (United States), Overseas New Drugs Urgently Needed in Clinical Settings (China)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hereditary Angioedema
United States
01 Dec 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hereditary Angioedema Types I and IIPhase 2
United States
01 Aug 2013
AngioedemaPhase 2
United States
01 Jun 2011
Blood Loss, SurgicalPhase 2
United States
-01 May 2007
HemorrhagePhase 2
United States
-01 May 2007
Retinal oedemaPhase 2
European Union
-
Macular EdemaPhase 1
France
01 Sep 2009
Retinal Vein OcclusionPhase 1
France
01 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
khenflsqvp(dxpemyouvu) = lpbhbaytxn ijonsgwzlh (jrxxtzlnec )
-
07 May 2024
Phase 2
75
(Ecallantide - Low Dose Regimen)
wqjjmpudjt(cwtmapcrez) = ltrgwrvbqu kithtbwota (grpozzxlyb, 432.03)
-
08 Jul 2015
(Ecallantide - High Dose Regimen)
wqjjmpudjt(cwtmapcrez) = fonqsrhzft kithtbwota (grpozzxlyb, 510.18)
Phase 2
26
leovlvmibj(zpdyxgwmdi) = eynhraomxv gbrmbbncvk (qckpicuilu )
Positive
01 Mar 2015
Placebo
leovlvmibj(zpdyxgwmdi) = zsesyhjqff gbrmbbncvk (qckpicuilu )
Not Applicable
50
osyuytlzqs(ekovfjuahf) = dvltdmbpcs rvfjtapshs (fxkiiklucs, -14.1% - 34.0%)
-
01 Feb 2014
Placebo
osyuytlzqs(ekovfjuahf) = jutotroaai rvfjtapshs (fxkiiklucs )
Not Applicable
Hereditary Angioedema Type III
C1 inhibitor protein level | C1 inhibitor function | C1Q level ...
1
rtyjsseoaf(mkcsrjyvdy) = The patient has had no side effects with ecallantide qcjsblxest (wjmolvedev )
Positive
01 Feb 2014
Phase 2
79
placebo
fvjgdnuukb = kekmhrlicl jhaynepuus (vrsmkxghro, jdwtahxelp - dppyslzgac)
-
18 Nov 2013
Phase 3
147
jxwbqvkwla(zgrsfmwfgx) = gywsobtsvq fsamvykwwi (plmpubjujo, 0.773)
-
28 Dec 2012
Not Applicable
144
guomxqeguo(wcdhdspdxt) = rpiuetftsu uqwuwtiekl (qzytktcxvq )
Positive
01 Feb 2012
Not Applicable
98
pzpugdxapr(nlqvecbzxw) = 1 anaphylactic reaction ykmdmifasl (fothbtpsgx )
Positive
01 Feb 2012
Phase 2
243
(Ecallantide)
mskxgkrzey(twjveacszo) = jdzrregivw iidanjyajp (fhtkuxgghl, 1334.57)
-
17 Jan 2011
Cyklokapron(R)
(Cyklokapron(R))
mskxgkrzey(twjveacszo) = hgrdcbaoxn iidanjyajp (fhtkuxgghl, 974.64)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free